Selskabets formål er at udføre farmakologiske og toksikologiske undersøgelser, biologiske styrkebestemmelser, biologiske kontrolundersøgelser og biologiske forskningsopgaver samt anden hermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 162.8 mio. | 3.7 mio. | 190.1 mio. | 26.3 mio. | 125 | |
CVR: 83090413
Secondary names: LAB RESEARCH DENMARK A/S, LAB SCANTOX A/S, SCANTOX BIOLOGISK LABORATORIUM A/S
Previous names: SCANTOX. BIOLOGISK LABORATORIUM A/S, LAB RESEARCH A/S, CITOXLAB SCANTOX A/S
3 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 1.003 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Scantox A/S demonstrates a solid financial trajectory, with revenue increasing from 48.5 million DKK in 2021 to 162.8 million DKK in 2025. However, profitability has fluctuated, peaking at 17.3 million DKK in 2023 before declining to 3.7 million DKK in 2025. The company's equity has shown growth, rising from 16.8 million DKK in 2021 to 26.3 million DKK in 2025, indicating a strengthening balance sheet. While the revenue trend is positive, the declining profit margins raise concerns about operational efficiency and cost management. Positioned within the research and experimental development sector, Scantox A/S is expanding but must address profitability challenges to sustain growth.
AI-generated summary
Companies in the same industry and area
CVR 26385121
CVR 29474613
CVR 30358287
CVR 34894221
CVR 39354829
Majbritt Brahe Salten joined the board
Kari Kaaber left the board
companydata.dk